Regression of Left Ventricular Hypertrophy in Primary Aldosteronism.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Goi Jessica, Burrello Jacopo, Schneider Holger, Petersenn Erik Johann, Zopp Stephanie, Capuzzo Virginia, García Cano Ana María, Caja Guayerbas Laura, Mena Ribas Elena, Sanmartín Sánchez Alicia, Parra Ramírez Paola, Martín Rojas-Marcos Patricia, Paja Fano Miguel, Díaz Guardiola Patricia, Rebollo Román Ángel, Moya Mateo Eva María, Gabriel Ruiz-Sanchez Jorge, González-Boillos Marga, Jaén Aguila Fernando, Perdomo Carolina María, Robles Lázaro Cristina, Recasens Mònica, Barahona San Millan Rebeca, Gómez-Hoyos Emilia, Picón César María José, Gutiérrez-Medina Sonsoles, Lamas Cristina, Casteras Anna, Mulatero Paolo, Reincke Martin, Araujo-Castro Marta, Adrenal Working Group of the Spanish Society of Endocrinology & Nutrition (SEEN)
Аннотация
METHODS: We retrospectively analyzed an international cohort of patients with primary aldosteronism from 36 referral centers in Spain, Italy, and Germany. Echocardiographic recordings were included at baseline and after at least 1 year of targeted treatment. Regression models were applied to identify parameters associated with LVH regression and changes in left ventricular mass index.
RESULTS: Among 1454 patients (mean age, 51 years; 58.7% men) with primary aldosteronism, baseline LVH prevalence was 49.4%. Aldosterone, blood pressure, male sex, number of antihypertensive medications, and diabetes were associated with LVH. Of 473 patients with follow-up echocardiography, 33.6% underwent adrenalectomy, 61.7% received MRA, and 4.7% were taking MRA postsurgery. After a median follow-up of 51 months, LVH regression was observed in 54.2% of patients (61.9% after adrenalectomy versus 48.6% with MRA treatment; P=0.043), and left ventricular mass index significantly decreased after both surgery and medical therapy. Higher pretreatment blood pressure and aldosterone levels were associated with a lower likelihood of LVH regression, regardless of treatment modality. Complete biochemical success was associated with greater left ventricular mass index reduction at follow-up.
CONCLUSIONS: LVH regressed in over half the patients after targeted treatment, with left ventricular mass index decreasing after both adrenalectomy and MRA therapy. Baseline aldosterone levels were associated with LVH regression, independently of blood pressure load.